← Back to Search

Other

VCTX211 for Type 1 Diabetes

Phase 1 & 2
Recruiting
Research Sponsored by CRISPR Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new treatment for people with Type 1 Diabetes using special insulin-making cells and a delivery device. The cells are edited to avoid immune attacks, and the device helps place them in the body.

Who is the study for?
This trial is for people who have had Type 1 Diabetes (T1D) for at least 5 years and are on a stable diabetes treatment plan. They can't join if they've used immunosuppressants recently, had certain organ transplants, other types of diabetes, gene therapy treatments, or frequent severe unexplained drops in blood sugar.
What is being tested?
The study is testing VCTX211, a new combination product to see how safe and effective it is for treating T1D. It's an early-stage trial where everyone gets the same treatment without any placebos or comparison groups.
What are the potential side effects?
While specific side effects aren't listed here, typical risks may include immune system reactions due to the nature of autoimmune disease treatments like inflammation or allergic responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: VCTX211 unitExperimental Treatment1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for autoimmune diseases often involve immune-modulating therapies that aim to reduce the abnormal immune response responsible for attacking the body's own tissues. For instance, intravenous immune globulin (IVIG) is used to modulate the immune system by providing antibodies that can neutralize harmful autoantibodies and reduce inflammation. In the context of Type 1 Diabetes (T1D), treatments like the VCTX211 combination product may focus on enhancing insulin production or protecting pancreatic beta cells from immune-mediated destruction. These mechanisms are crucial for patients as they help in managing disease symptoms, preventing organ damage, and improving overall quality of life by restoring normal immune function and preserving essential physiological processes.
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?Graves' disease: developments in first-line antithyroid drugs in the young.Clinical characteristics of chronic idiopathic thrombocytopenia in Chinese children.

Find a Location

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor
8 Previous Clinical Trials
852 Total Patients Enrolled
ViaCyteIndustry Sponsor
6 Previous Clinical Trials
160 Total Patients Enrolled
Sandeep Soni, MDStudy DirectorCRISPR Therapeutics
5 Previous Clinical Trials
33 Total Patients Enrolled
Manasi Jaiman, MD, MPHStudy DirectorViaCyte
2 Previous Clinical Trials
56 Total Patients Enrolled

Media Library

VCTX211 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05565248 — Phase 1 & 2
Endocrine Disorders Research Study Groups: VCTX211 unit
Endocrine Disorders Clinical Trial 2023: VCTX211 Highlights & Side Effects. Trial Name: NCT05565248 — Phase 1 & 2
VCTX211 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05565248 — Phase 1 & 2
~5 spots leftby Apr 2025